"Intravitreal Injections" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The administration of substances into the VITREOUS BODY of the eye with a hypodermic syringe.
| Descriptor ID |
D058449
|
| MeSH Number(s) |
E02.319.267.530.475.500
|
| Concept/Terms |
Intravitreal Injections- Intravitreal Injections
- Injection, Intravitreal
- Injections, Intravitreal
- Intravitreal Injection
|
Below are MeSH descriptors whose meaning is more general than "Intravitreal Injections".
Below are MeSH descriptors whose meaning is more specific than "Intravitreal Injections".
This graph shows the total number of publications written about "Intravitreal Injections" by people in this website by year, and whether "Intravitreal Injections" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2010 | 0 | 1 | 1 |
| 2013 | 0 | 1 | 1 |
| 2014 | 0 | 1 | 1 |
| 2015 | 0 | 1 | 1 |
| 2016 | 0 | 4 | 4 |
| 2017 | 0 | 1 | 1 |
| 2018 | 0 | 2 | 2 |
| 2019 | 0 | 3 | 3 |
| 2020 | 1 | 1 | 2 |
| 2021 | 0 | 3 | 3 |
| 2022 | 0 | 4 | 4 |
| 2023 | 0 | 3 | 3 |
| 2024 | 2 | 3 | 5 |
| 2025 | 0 | 2 | 2 |
| 2026 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Intravitreal Injections" by people in Profiles.
-
A method to quantify ligand-neuron binding in vivo. J Neurosci Methods. 2027 Jan; 437:110911.
-
Peri-Event Intravitreal Anti-VEGF and Systemic Outcomes After Stroke or Myocardial Infarction. JAMA Ophthalmol. 2026 05 01; 144(5):415-422.
-
Fluocinolone Acetonide Implant as a Baseline Therapy for Diabetic Macular Edema: Results from the Randomized Phase 4 NEW DAY Study. Ophthalmology. 2026 Jul; 133(7):837-851.
-
Avacincaptad Pegol for Geographic Atrophy Secondary to Age-Related Macular Degeneration: Two-Year Efficacy and Safety Results from the GATHER2 Phase 3 Trial. Ophthalmology. 2026 04; 133(4):451-465.
-
Short-term effects of tetracycline use in patients with diabetic retinopathy. Can J Ophthalmol. 2025 12; 60(6):e858-e868.
-
Use of Home Optical Coherence Tomography for Retinal Diseases. Int Ophthalmol Clin. 2025 Jan 01; 65(1):41-46.
-
Therapies for Central Serous Chorioretinopathy: A Report by the American Academy of Ophthalmology. Ophthalmology. 2025 03; 132(3):343-353.
-
International Classification System for Ocular Complications of Anti-VEGF Agents in Clinical Trials. Ophthalmology. 2024 12; 131(12):1457-1467.
-
Biophysics of ophthalmic medications during spaceflight: Principles of ocular fluid dynamics and pharmacokinetics in microgravity. Life Sci Space Res (Amst). 2024 Aug; 42:53-61.
-
Treatment of Noninfectious Uveitic Macular Edema with Periocular and Intraocular Corticosteroid Therapies: A Report by the American Academy of Ophthalmology. Ophthalmology. 2024 09; 131(9):1107-1120.